Impact of beta‐blocker use on the long‐term outcomes of heart failure patients with chronic obstructive pulmonary disease

AIMS: The number of patients with both chronic obstructive pulmonary disease (COPD) and heart failure (HF) is increasing in Asia, and these conditions often coexist. We previously revealed a tendency of beta‐blocker underuse among patients with HF with reduced ejection fraction (HFrEF) and COPD in Asian countries other than Japan. Here, we evaluated the impact of cardio‐selective beta‐blocker use on the long‐term outcomes of patients with HF and COPD. METHODS AND RESULTS: Among the 5232 patients with HFrEF (left ventricular ejection fraction of <40%) prospectively enrolled from 11 Asian regions in the ASIAN‐HF registry, 412 (7.9%) had a history of COPD. We compared the clinical characteristics and long‐term outcomes of the patients with HF and COPD according to the use and type of beta‐blockers used: cardio‐selective beta‐blockers (n = 149) vs. non‐cardio‐selective beta‐blockers (n = 124) vs. no beta‐blockers (n = 139). The heart rate was higher, and the outcome was poorer in the no beta‐blocker group than in the beta‐blocker groups. The 2 year all‐cause mortality was significantly lower in the non‐cardio‐selective beta‐blocker group than in the no beta‐blocker group. Further, the cardiovascular mortality significantly decreased in the non‐cardio‐selective beta‐blocker group before (hazard ratio: 0.36; 95% confidence interval: 0.18–0.73; P = 0.004) and after adjustments (hazard ratio: 0.37; 95% confidence interval: 0.19–0.73; P = 0.005), but not in the cardio‐selective beta‐blocker group. CONCLUSIONS: Beta‐blockers reduced the all‐cause mortality of patients with HFrEF and COPD after adjusting for age and heart rate, although the possibility of selection bias could not be completely excluded due to multinational prospective registry.